atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
Capital planning in healthcare is not merely an administrative obligation—it is a strategic discipline that shapes clinical capabilities, operational resilience and financial health.
Recognising and addressing common planning mistakes is essential to sustaining high-quality, efficient care in an increasingly complex…
The US Food and Drug Administration has approved the first eye drop that could allow users to ditch their bifocals—or at least rely on them far less often. Developed by the pharmaceutical company LENZ, VIZZ is an aceclidine ophthalmic treatment in the form of…
Attendees
Sponsors and Exhibitors
Contact us